PMC:7200337 / 99234-99542 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T752","span":{"begin":250,"end":258},"obj":"Body_part"}],"attributes":[{"id":"A752","pred":"fma_id","subj":"T752","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T573","span":{"begin":46,"end":54},"obj":"Disease"}],"attributes":[{"id":"A573","pred":"mondo_id","subj":"T573","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1034","span":{"begin":24,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T1035","span":{"begin":108,"end":114},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3279","span":{"begin":151,"end":153},"obj":"Gene"},{"id":"3280","span":{"begin":72,"end":74},"obj":"Gene"},{"id":"3293","span":{"begin":46,"end":56},"obj":"Species"},{"id":"3294","span":{"begin":163,"end":171},"obj":"Species"},{"id":"3299","span":{"begin":101,"end":104},"obj":"Chemical"},{"id":"3301","span":{"begin":154,"end":162},"obj":"Disease"}],"attributes":[{"id":"A3279","pred":"tao:has_database_id","subj":"3279","obj":"Gene:6999"},{"id":"A3280","pred":"tao:has_database_id","subj":"3280","obj":"Gene:6999"},{"id":"A3293","pred":"tao:has_database_id","subj":"3293","obj":"Tax:2697049"},{"id":"A3294","pred":"tao:has_database_id","subj":"3294","obj":"Tax:9606"},{"id":"A3301","pred":"tao:has_database_id","subj":"3301","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron."}

{"project":"LitCovid-sentences","denotations":[{"id":"T582","span":{"begin":0,"end":308},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similar studies are now focused on the use of SARS-CoV-2 or derivatives to generate highly effective nAb in animal models, which can be directly given to infected patients, and efforts are already underway with estimates of clinical trials of pooled antibody cocktails beginning in early summer by Regeneron."}